Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesImmunology/RheumatologySierra Health and Life IV Tocilizumab Coverage Upd…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Currentsierra health and lifePolicy 2026D0043Y

    Tocilizumab (Actemra®, Tofidence™, & Tyenne®) Injection for Intravenous Infusion – Commercial Medical Benefit Drug Policy

    Customize your policy alerts

    Sign up for sierra health and life Policy 2026D0043Y alerts

    Get alerted when Policy 2026D0043Y changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Medical benefit drug policy governing use, prior authorization criteria, and coding for intravenous tocilizumab products (Actemra, Tofidence, Tyenne) across multiple indications including PJIA, SJIA, RA, GCA, CRS, acute GVHD, and immune checkpoint inhibitor-related toxicities. This part (1 of 2) contains preferred-product rules, indication-specific medical necessity criteria, and applicable procedure/diagnosis codes.

    Policy Summary
    Payersierra health and life
    PolicyTocilizumab (Actemra®, Tofidence™, & Tyenne®) Injection for Intravenous Infusion – Commercial Medical Benefit Drug Policy
    Policy CodePolicy 2026D0043Y
    Change TypePreferred-product and terminology updates
    Effective DateMar 1, 2026
    Next Review Date
    Key ActionSubmit prior authorization with documentation of required trials/intolerance and prescriber attestations; initial approvals limited to ≤12 months for chronic indications and ≤4 doses for CRS/GVHD/checkpoint toxicities.
    SourceLink
    POLICY UPDATE CHANGES

    Added language to indicate any U.S. Food and Drug Administration approved tocilizumab product is considered preferred; products not listed will be considered non-preferred until reviewed by UnitedHealthcare.

    Replaced 'Targeted immunomodulator' with 'systemic targeted immunomodulator' and replaced 'Biologic or targeted synthetic DMARD' with 'systemic targeted immunomodulator' across diagnosis-specific criteria.

    Updated examples of systemic targeted immunomodulators for rheumatoid arthritis (added Cimzia, Enbrel, Orencia; nomenclature updates for adalimumab and Xeljanz/XR).

    Updated list of systemic targeted immunomodulators that must not be received in combination with tocilizumab for specific indications; for Giant Cell Arteritis added Kevzara (sarilumab) and removed several agents including adalimumab and certolizumab.

    Updated CMS and References sections to reflect the most current information.

    7Indications with criteria included in Part 1
    3Dose-limit indications (CRS/GVHD/checkpoint toxicities)
    3FDA-indicated major conditions listed
    1Policy revision date entries
    100+ICD-10 codes listed

    Coverage Summary

    This medical-benefit policy (Part 1 of 2) governs intravenous (IV) formulations of tocilizumab — specifically Actemra (tocilizumab), Tofidence (tocilizumab‑bavi), and Tyenne (tocilizumab‑aazg) — and defines prior authorization, coding, and indication‑specific medical necessity criteria across multiple indications. Covered indications addressed in this part include polyarticular juvenile idiopathic arthritis (PJIA), systemic juvenile idiopathic arthritis (SJIA), moderately to severely active rheumatoid arthritis (RA), giant cell arteritis (GCA), chimeric antigen receptor (CAR) T cell–related cytokine release syndrome (CRS), steroid‑refractory acute graft‑versus‑host disease (GVHD), and severe immune checkpoint inhibitor–related toxicities. The policy includes preferred‑product rules (Actemra and Tyenne preferred), criteria for use of non‑preferred IV biosimilars (e.g., Tofidence), and the diagnosis‑specific medical necessity criteria and applicable procedure/diagnosis codes for IV tocilizumab.

    Key Thresholds
    Preferred-product trial duration>= 14 weeks of Actemra or Tyenne
    CRS/GVHD dose limit<= 4 doses (initial authorization)
    Initial auth duration for chronic indications<= 12 months
    High-dose steroid trial for checkpoint toxicity
    Policy Summary
    Payersierra health and life
    PolicyTocilizumab (Actemra®, Tofidence™, & Tyenne®) Injection for Intravenous Infusion – Commercial Medical Benefit Drug Policy
    Policy CodePolicy 2026D0043Y
    Change TypePreferred-product and terminology updates
    Effective DateMar 1, 2026
    Next Review Date
    Key ActionSubmit prior authorization with documentation of required trials/intolerance and prescriber attestations; initial approvals limited to ≤12 months for chronic indications and ≤4 doses for CRS/GVHD/checkpoint toxicities.
    SourceLink
    On This Page
    Coverage SummaryPreferred Product Exception CriteriaInitial Therapy Criteria (Diagnosis-specific)Continuation Therapy CriteriaDose-Limited Indications (Short-course/Acute)Concurrent Therapy & ExclusionsProvider Actions & RequirementsApplicable CodesClinical Evidence & ReferencesBackground & DefinitionsRevision History
    >= 7 days without improvement

    Preferred Product Exception Criteria

    Preferred Product Criteria

    Treatment with Tofidence or other non-preferred tocilizumab biosimilar is medically necessary for the indications specified in this policy when the following conditions are met:

    ALL of the following

    • One of the following must be met:

      • 14-week trial + physician attestation

        • Documentation of a trial of at least 14 weeks of Actemra or Tyenne resulting in minimal clinical response to therapy and residual disease activity.
        • Physician attests that in their clinical opinion, the clinical response would be expected to be superior with Tofidence or other tocilizumab biosimilar product than experienced with Actemra or Tyenne.
      • Intolerance/contraindication + attestation

        • Documentation of intolerance, contraindication, or adverse event to Actemra or Tyenne.
        • Physician attests that in their clinical opinion, the same intolerance, contraindication, or adverse event would not be expected to occur with Tofidence or other tocilizumab biosimilar product.
    • Patient has not had a loss of a favorable response after established maintenance therapy with Actemra or Tyenne or other tocilizumab biosimilar product.

      Required in addition to one of the branches above.

    General Coverage Rationale / Preferred Product: Actemra (tocilizumab) and Tyenne (tocilizumab-aazg) are the preferred tocilizumab products. Coverage for Tofidence (tocilizumab-bavi) or any U.S. Food and Drug Administration–approved tocilizumab product not listed by name in this policy will be considered non-preferred until reviewed and will be provided only when the Preferred Product Criteria above and the applicable Diagnosis-Specific Coverage Criteria are met. Members already receiving a non-preferred tocilizumab product will be required to change therapy to Actemra or Tyenne unless they meet the Preferred Product Criteria for continuation of the non-preferred product.

    Policy note: Diagnosis-Specific Coverage Criteria (summary of revisions): The Diagnosis-Specific Criteria clarify initial and continuation requirements across labeled indications (e.g., rheumatoid arthritis, systemic and polyarticular juvenile idiopathic arthritis). Revisions emphasize: documentation of FDA‑labeled dosing, prescriber attestations when self-administration is not feasible, prior failure/intolerance to non-biologic DMARD(s) or other specified therapies where noted, and authorization durations (initial and continuation) generally limited to no more than 12 months. These criteria must be met in addition to the Preferred Product requirements for coverage of non-preferred tocilizumab products.

    Initial Therapy Criteria (Diagnosis-specific)

    Diagnosis-Specific Criteria: Polyarticular Juvenile Idiopathic Arthritis (PJIA)

    Tocilizumab is proven and medically necessary when ALL of the following criteria are met.

    • Diagnosis of polyarticular juvenile idiopathic arthritis (PJIA)
    • Dosing: Tocilizumab is dosed according to FDA labeled dosing for polyarticular juvenile idiopathic arthritisper FDA
    • No combination therapy: Patient is not receiving Tocilizumab in combination with a systemic targeted immunomodulator for treatment of the same indication (examples: adalimumab, certolizumab (Cimzia), etanercept (Enbrel), baricitinib (Olumiant), abatacept (Orencia), upadacitinib (Rinvoq), golimumab (Simponi), tofacitinib (Xeljanz/XR))

      Examples listed in policy

    • Prescriber attestation (IV route): Prescriber attestation that the patient or caregiver are not able to be trained or are physically unable to administer FDA-labeled self-administered Tocilizumab; prescriber must submit explanation; prescriber must be or consult a rheumatologist

      Applies when IV route is used due to inability to self-administer

    • Initial authorization: For initial therapy: initial authorization is for no more than 12 months<= 12 months
    • Continuation of therapy: For continuation therapy: patient has previously received IV Tocilizumab; documentation of positive clinical response; Tocilizumab dosed per FDA; patient not receiving Tocilizumab in combination with a systemic targeted immunomodulator; authorization for no more than 12 months<= 12 months

      Appears in both initial and continuation criteria variants

    Diagnosis-Specific Criteria: Rheumatoid Arthritis (RA)

    Tocilizumab is proven and medically necessary when ALL of the following criteria are met.

    • Diagnosis of moderately to severely active rheumatoid arthritis (RA)
    • One of the following

      • Prior non-biologic DMARD failure: History of failure, contraindication, or intolerance to at least one non-biologic DMARD (e.g., methotrexate, leflunomide, sulfasalazine, hydroxychloroquine, minocycline)
      • Prior systemic targeted immunomodulator: Patient has been previously treated with a systemic targeted immunomodulator FDA-approved for RA (examples: adalimumab, certolizumab (Cimzia), etanercept (Enbrel), baricitinib (Olumiant), abatacept (Orencia), upadacitinib (Rinvoq), golimumab (Simponi), tofacitinib (Xeljanz/XR))
      • Currently on Tocilizumab:

    Diagnosis-Specific Criteria: Systemic Juvenile Idiopathic Arthritis (SJIA)

    Tocilizumab is proven and medically necessary when ALL of the following criteria are met.

    • Diagnosis of systemic juvenile idiopathic arthritis (SJIA)
    • Dosing: Tocilizumab is dosed according to FDA labeled dosing for systemic juvenile idiopathic arthritisper FDA
    • No combination therapy: Patient is not receiving Tocilizumab in combination with a systemic targeted immunomodulator for the same indication (examples listed in policy)
    • Initial authorization is for no more than 12 months<= 12 months

    Diagnosis-Specific Criteria: Giant Cell Arteritis (GCA)

    Tocilizumab is proven and medically necessary when ALL of the following criteria are met.

    • Diagnosis of giant cell arteritis (GCA)
    • Dosing: Tocilizumab is dosed according to FDA labeled dosing for giant cell arteritisper FDA
    • No combination therapy: Patient is not receiving Tocilizumab in combination with a systemic targeted immunomodulator for the same indication (examples: Kevzara (sarilumab), Orencia (abatacept), Rinvoq (upadacitinib))

      Examples listed in policy

    • Initial authorization is for no more than 12 months<= 12 months

    Continuation Therapy Criteria

    Continuation Therapy Elements

    Continuation Therapy Requirements (applies across PJIA, RA, SJIA, GCA)

    • Prior IV use: Patient has previously received Tocilizumab injection for intravenous infusion
    • Positive response: Documentation of positive clinical response to Tocilizumab
    • Dosing: Tocilizumab is dosed according to FDA labeled dosing for the specific indicationper FDA
    • No concomitant systemic targeted immunomodulator: Patient is not receiving Tocilizumab in combination with a systemic targeted immunomodulator for treatment of the same indication (examples listed in each diagnosis-specific section)
    • Authorization time limit: Authorization for continuation is for no more than 12 months for chronic indications<= 12 months

    Dose-Limited Indications (Short-course/Acute)

    Diagnosis-Specific Criteria: Cytokine Release Syndrome (CRS)

    Tocilizumab is proven and medically necessary when ALL of the following criteria are met.

    • Diagnosis of cytokine release syndrome (CRS)
    • Therapy received: Patient has received treatment with CAR T-cell therapy (e.g., tisagenlecleucel, axicabtagene ciloleucel) or CD3-directed therapy (e.g., blinatumomab, teclistamab)
    • Dosing: Tocilizumab is dosed according to FDA labeled dosing for CRSper FDA
    • Initial authorization is for no more than 4 doses<= 4 doses
    • Continuation criteria: For continuation of therapy: documentation of positive clinical response; patient continues to experience signs and symptoms of CRS; dosing per FDA; authorization for no more than 4 doses<= 4 doses

    Diagnosis-Specific Criteria: Acute Graft-Versus-Host Disease (GVHD)

    Tocilizumab is proven and medically necessary for steroid-refractory acute GVHD when ALL of the following criteria are met.

    • Diagnosis of steroid-refractory acute graft-versus-host disease (GVHD)
    • One of the following

      • Combination with steroids: Patient is receiving Tocilizumab in combination with systemic corticosteroids
      • Steroid intolerance: Patient is intolerant to systemic corticosteroid therapy
    • Initial authorization is for no more than 4 doses<= 4 doses

    Diagnosis-Specific Criteria: Immune Checkpoint Inhibitor-Related Toxicities

    Tocilizumab is proven and medically necessary when ALL of the following criteria are met.

    • Checkpoint therapy: Patient has recently received checkpoint inhibitor therapy (examples: pembrolizumab, nivolumab)
    • Diagnosis of severe immunotherapy-related inflammatory arthritis
    • Steroid trial: No symptom improvement after 7 days of starting high-dose corticosteroids>= 7 days
    • Infliximab failure: History of failure, contraindication, or intolerance to infliximab
    • One of the following

    Concurrent Therapy & Exclusions

    Policy rule: Patients must not receive tocilizumab in combination with certain systemic targeted immunomodulators for the same indication. The policy replaces prior terminology ('Targeted immunomodulator' and 'Biologic or targeted synthetic DMARD') with the updated term 'systemic targeted immunomodulator' across diagnosis‑specific criteria, and the examples of agents that must not be used concomitantly are specified within each indication section.

    Diagnosis‑specific note on prohibited combinations: the policy provides updated lists of systemic targeted immunomodulators that must not be co‑administered with tocilizumab for the same indication. For Giant Cell Arteritis, the policy specifically adds Kevzara (sarilumab) to the list of agents not to be combined and removes several agents (including adalimumab, certolizumab [Cimzia], etanercept [Enbrel], baricitinib [Olumiant], golimumab [Simponi], and tofacitinib [Xeljanz]) from that GCA exclusion list. Similar updated example lists are provided for PJIA, RA, and SJIA.

    Provider Actions & Requirements

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for intravenous tocilizumab. Initial authorizations are limited to no more than 12 months for chronic rheumatologic indications (PJIA, SJIA, RA, GCA) and no more than 4 doses for CRS, steroid-refractory acute GVHD, and checkpoint inhibitor–related toxicities.

    • J3262
    • Q5133
    • Q5135
    Documentation Required

    Documentation Required

    Submit documentation to support requests including prior treatment trials or reasons for non-preferred substitution (for example, documentation of a trial of at least 14 weeks of Actemra or Tyenne when requesting a non-preferred tocilizumab), documentation of intolerance/contraindication/adverse event to preferred products, and physician/prescriber attestations (e.g., that clinical response would be expected to be superior with the requested non-preferred product or that the same adverse event would not be expected to recur). Also include prescriber attestation and explanation when IV route is used because the patient or caregiver cannot be trained or is physically unable to self-administer.

    Documentation Required

    Continuation Evidence

    For continuation/renewal requests provide evidence of prior IV tocilizumab use and documentation of a positive clinical response. For CRS or acute GVHD continuation requests, also document that the patient continues to experience signs and symptoms of CRS or ongoing acute GVHD when requesting additional doses.

    Step Therapy

    Preferred Product Step Requirement

    Members receiving a non-preferred tocilizumab (for example, Tofidence) will be required to change therapy to a preferred product (Actemra or Tyenne) to continue coverage unless they meet the preferred-product exception criteria specified in the policy.

    Documentation Required

    Verify Member Benefits

    Verify the member-specific benefit plan document and any applicable federal or state mandates before making a coverage determination; the member-specific plan governs in the event of a conflict.

    Prior Authorization

    Non-Listed Products Considered Non-Preferred

    Tocilizumab products not listed by name in this policy will be considered non-preferred until reviewed by UnitedHealthcare; such products require review/prior authorization per the plan prior to coverage.

    Documentation Required

    Use of Objective Evidence-Based Rationale

    UnitedHealthcare may rely on objective, evidence-based rationale when making determinations. In the absence of Medicare NCD/LCD guidance, Medicare Advantage Organizations may create coverage determinations using authoritative evidence. UnitedHealthcare may also use third-party tools (e.g., InterQual) to assist administration.

    Applicable Codes

    Covered HCPCS/J-codes for tocilizumabHCPCSCovered
    J3262Injection, tocilizumab, 1 mg
    Q5133Tocilizumab-bavi, biosimilar, 1 mg
    Q5135Tocilizumab-aazg, biosimilar, 1 mg
    ICD-10 Examples (not exhaustive)ICD-10
    M08.3Systemic juvenile rheumatoid arthritis
    M08.2APolyarticular juvenile rheumatoid arthritis, bilateral involvement
    M08.88Other juvenile rheumatoid arthritis, multiple sites

    Clinical Evidence & References

    2-3yrACT-RAY trial: 2- and 3-year results showed treat-to-target can achieve sustained drug-free remission in a subset
    50.4%Proportion discontinuing TCZ by week 104 in ACT-RAY (50.4%); 11.8% achieved total drug-free remission
    ≤4NCCN/CAR T guidance: assess need up to a maximum of 4 doses for CRS
    GuidelinesMultiple guideline references support use across indications (ACR RA 2021; ACR JIA 2019; ACR/VF GCA 2021; NCCN)

    Evidence: ACT‑RAY trial (Huizinga et al.) — 2‑ and 3‑year results from the ACT‑RAY study showed that treat‑to‑target strategies with tocilizumab can achieve sustained drug‑free remission in a subset of RA patients, with similar safety profiles between add‑on and switch strategies and most patients demonstrating minimal radiographic progression at week 104.

    Guidelines and compendia: the policy references key guidance supporting tocilizumab use including the 2021 American College of Rheumatology (ACR) guideline for rheumatoid arthritis, the 2019 ACR/Arthritis Foundation guideline for juvenile idiopathic arthritis, the 2021 ACR/Vasculitis Foundation guideline for giant cell arteritis, and recommendations from the NCCN Drugs & Biologics Compendium (which includes tocilizumab recommendations for CRS, acute GVHD, and certain immune‑related toxicities).

    Background & Definitions

    Background: This policy applies to intravenous formulations of tocilizumab (Actemra, Tofidence, Tyenne). Self‑administered subcutaneous tocilizumab formulations (Actemra and Tyenne when available for subcutaneous use) are managed under the pharmacy benefit except where the member's plan documents or specified delegated‑plan exceptions indicate medical‑benefit coverage. The policy designates Actemra and Tyenne as preferred products for IV tocilizumab; non‑preferred biosimilars (for example, Tofidence or other FDA‑approved tocilizumab products not listed by name) require documentation meeting the preferred‑product criteria (such as trial duration, intolerance/contraindication, and physician attestation) to establish medical necessity.

    TermDefinition
    Tocilizumab
    Refers to all tocilizumab products including Actemra (tocilizumab), Tofidence (tocilizumab-bavi), and Tyenne (tocilizumab-aazg).
    Systemic targeted immunomodulator
    Revised policy term encompassing biologic DMARDs and targeted synthetic DMARDs used systemically for conditions such as rheumatoid arthritis.

    Revision History

    03/01/2026material_addedLatest

    Added language that any U.S. Food and Drug Administration–approved tocilizumab product not listed by name in the policy will be considered non-preferred until reviewed by UnitedHealthcare; clarified preferred products are Actemra and Tyenne and non-preferred biosimilars (e.g., Tofidence) require meeting preferred product criteria.

    03/01/2026material_revised

    Replaced terminology across diagnosis-specific criteria: 'Targeted immunomodulator' and 'Biologic or targeted synthetic DMARD' were changed to 'systemic targeted immunomodulator'.

    03/01/2026material_revised

    Updated examples of systemic targeted immunomodulators for rheumatoid arthritis: added Cimzia (certolizumab), Enbrel (etanercept), Orencia (abatacept); updated nomenclature for adalimumab and Xeljanz to 'adalimumab' and 'Xeljanz/Xeljanz XR (tofacitinib)'.

    03/01/2026material_revised

    Updated list of systemic targeted immunomodulators that must not be received in combination with tocilizumab for specific indications; for Giant Cell Arteritis added Kevzara (sarilumab) and removed several agents including adalimumab, certolizumab (Cimzia), etanercept (Enbrel), baricitinib (Olumiant), golimumab (Simponi), and tofacitinib (Xeljanz).

    03/01/2026clarified

    Updated CMS and References sections to reflect current information.

    Patient is currently on Tocilizumab
  1. Prescriber attestation (IV route): Prescriber attestation that the patient or caregiver are not able to be trained or are physically unable to administer FDA-labeled self-administered Tocilizumab; prescriber must submit explanation
  2. Dosing: Tocilizumab is dosed according to FDA labeled dosing for rheumatoid arthritisper FDA
  3. No combination therapy: Patient is not receiving Tocilizumab in combination with a systemic targeted immunomodulator for the same indication (examples listed in policy)
  4. Rheumatology involvement: Prescribed by or in consultation with a rheumatologist
  5. Initial authorization is for no more than 12 months<= 12 months
  6. Continuation criteria: For continuation of therapy: patient has previously received IV Tocilizumab; documentation of positive clinical response; prescriber attestation re: inability to self-administer; dosing per FDA; no concomitant systemic targeted immunomodulator; authorization for no more than 12 months<= 12 months
  7. Continuation criteria: For continuation of therapy: patient has previously received IV Tocilizumab; documentation of positive clinical response; Tocilizumab dosed per FDA; patient not receiving concomitant systemic targeted immunomodulator; authorization for no more than 12 months<= 12 months
  8. Prescriber attestation (IV route): When IV route is used due to inability to self-administer: prescriber attestation required; prescriber must be or consult rheumatologist
  9. Continuation criteria: For continuation of therapy: patient has previously received IV Tocilizumab; documentation of positive clinical response; Tocilizumab dosed per FDA; patient not receiving concomitant systemic targeted immunomodulator; authorization for no more than 12 months<= 12 months
  10. Prescriber attestation (IV route): When IV route is used due to inability to self-administer: prescriber attestation required; prescriber must be or consult rheumatologist
  11. Continuation criteria: For continuation of therapy: documentation of positive clinical response; patient continues to experience acute GVHD; one of the above corticosteroid combination/intolerance conditions must apply; authorization for no more than 4 doses<= 4 doses
    • Combination with steroids: Patient is receiving Tocilizumab in combination with systemic corticosteroids
    • Steroid intolerance: Patient is intolerant to systemic corticosteroid therapy
  12. Authorization is for no more than 4 doses<= 4 doses